Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of a DNA Priming and MVA Boosting Strategy of HIV Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Age: 18 to 26 years~2. Willing to undergo HIV (Human Immunodeficiency Virus) counseling and testing~3. Have a negative antigen/antibody or antibody ELISA for HIV infection~4. Able to give informed consent~5. Satisfactory completion of an assessment of understanding prior to enrolment defined as 89% correct answers after three opportunities to take the test~6. Basic abilities to read and write~7. Resident in Maputo, and willing to remain so for the duration of the study~8. At low risk of HIV infection, defined as the absence of an identifiable risk factor/ behavior (their presence is therefore an exclusion criteria):~   * sexual partner with HIV~  * sexual partner with unknown HIV serostatus who is also unwilling to use protective condoms consistently in all sexual relations~  * sexual partner is known to be at high risk for HIV~  * more than one sexual partner in the last 6 months~  * history of being an alcoholic \[as medically defined or more than 35 units /week\]~  * history of Sexually Transmitted Infection (STI) within past 6 months~9. Verbal assurances that adequate birth control methods are used not to conceive/father a child during the study and up to 3 months after the last vaccine injection.~10. Women shall have a negative urine pregnancy test~11. Be willing to practice safe sex for the duration of the study to avoid sexually transmitted infections including HIV~12. Good health as determined by medical history, physical examination, clinical judgment and by key laboratory parameters as judged by the study physician.~13. Laboratory criteria:~    * Hemoglobin \>10.5g/dl~   * White blood cell count \<13,000/mm3~   * Neutrophils \>1,300/mm3~   * Lymphocytes \>1.000/ mm3~   * Platelets \>120,000/ mm3~   * Random Blood Glucose \< 6.44 mmol/L; if elevated, then a Fasting Blood Glucose \< 6.11mmol/L (according to DAIDS Table for Lab Criteria)~   * Bilirubin \<1.25 x uln~   * Alanine transaminase (ALT) \<1.25 x uln~   * Urine dipstick for protein and blood: negative or trace. (If either is ¿ 1+, complete urinalysis (UA) will be performed.~Exclusion Criteria:~1. At risk of HIV infection as mentioned above in the inclusion criteria~2. Active tuberculosis or other systemic infectious process elicited by review of systems, physical examination and laboratory detection~3. A history of immunodeficiency, chronic illness requiring continuous or frequent medical intervention~4. Autoimmune disease by history and physical examination~5. Hives or recurrent hives and severe eczema~6. A history of psychiatric, medical (including traditional medicine) and/or substance abuse problems during the past 6 months that the investigator believes would adversely affect the volunteer's ability to participate in the trial~7. History of epilepsy, or currently taking anti-epileptics~8. Received blood or blood products or immunoglobulins in the past 3 months~9. Receiving immunosuppressive therapy such as systemic corticosteroids or cancer chemotherapy~10. Use of experimental therapeutic agents within 30 days of study entry~11. Reception of any live, attenuated vaccine within 60 days of study entry.~12. Abnormality in Electrocardiogram (ECG) that could indicate risk or make interpretation of vaccine effects difficult according to the study operating procedures~13. Previously received an HIV vaccine candidate~14. History of severe local or general reaction to vaccination defined as:~    * Local: Extensive, indurate redness and swelling involving most of the major circumference of the arm, not resolving within 72 hours~   * General: Fever \>= 39.5 0C within 48 hours; anaphylaxis; bronchospasm; laryngeal edema; collapse; convulsions or encephalopathy within 72 hours~15. Being a lactating mother~16. Study site employees who are involved in the protocol and may have direct access to the immunogenicity results~17. Unlikely to comply with protocol as judged by the principal investigator or his designate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 26 Years
- Healthy Volunteers: t

Study Arms:
- IA (Type: ACTIVE_COMPARATOR): 600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 108 pfu i.m. MVA boosting at weeks 24 and 36
- IB (Type: PLACEBO_COMPARATOR): 2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 saline solution i.m at weeks 24 and 36
- IIA (Type: ACTIVE_COMPARATOR): 1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12;108 pfu i.m. MVA boosting at weeks 24 and 36
- IIB (Type: PLACEBO_COMPARATOR): 2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36

Based on this trial design, predict the completion outcome and termination type (if applicable).